Oxervate
Showing 1 - 10 of 10
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Not yet recruiting
- Neurotrophic Keratitis
- Cenegemin in the DEFENDO Study
-
San Diego, California
- +2 more
Dec 12, 2022
Neurotrophic Ulcer Following Treatment With Oxervate
Recruiting
- Neurotrophic Ulcer
- +3 more
- Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
-
Manhasset, New YorkSightMD
May 3, 2022
Dry Eye Syndrome Trial in Italy, United States (Oxervate, Vehicle)
Active, not recruiting
- Dry Eye Syndrome
- Oxervate
- Vehicle
-
Glendale, California
- +10 more
Feb 1, 2023
Corneal Disease, Neuropathy Trial in Boston (Cenegermin-Bkbj)
Withdrawn
- Corneal Disease
- Neuropathy
-
Boston, MassachusettsTufts Medical Center
Jan 18, 2023
Corneal Nerves After Treatment With Cenegermin
Recruiting
- Neurotrophic Keratitis
- Cenegermin Ophthalmic Solution [Oxervate]
-
Los Angeles, CaliforniaUniversity of California, Los Angeles
Oct 14, 2022
Dry Eye Trial in Italy, United States (Oxervate, Vehicle)
Active, not recruiting
- Dry Eye
- Oxervate
- Vehicle
-
Glendale, California
- +10 more
Oct 24, 2022
Nerve Growth Factor for the Treatment of Cornea Disease
Completed
- Neurotrophic Keratitis
-
Stanford, CaliforniaStanford University
Dec 10, 2021
Renewal of Corneal Nerves Structure and Function in Neurotrophic
Completed
- Neurotrophic Keratopathy
- Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops
-
Chieti, ItalyOphtalmology Clinic, G.d'Annunzio University
Mar 3, 2020
Optic Pathway Glioma Trial in Rome (CHF6467, Placebo)
Not yet recruiting
- Optic Pathway Glioma
- CHF6467
- Placebo
-
Rome, ItalyCatholic University, Policlinico A. Gemelli (Hospital)
Feb 17, 2023